|Bid||29.22 x 1300|
|Ask||29.28 x 3100|
|Day's Range||28.84 - 29.38|
|52 Week Range||20.83 - 39.68|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.58|
LONDON, March 11, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and.
LONDON, Feb. 12, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study.
LONDON, Feb. 08, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March.
LONDON, Jan. 07, 2019 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th.
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – –.
Nov 29 (Reuters) - Innovent Biologics Inc: * HAS ENTERED INTO A GLOBAL COLLABORATION AGREEMENT WITH HUTCHISON CHINA MEDITECH LIMITED * UNDER AGREEMENT, UNIT INNOVENT SUZHOU AND HUTCHISON MEDIPHARMA TO ...
LONDON, Nov. 26, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the.
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer. It is one of the first modern medicines discovered and developed in China, and the speedy green light from Chinese authorities is further evidence of the country's progress in speeding up drug approvals.
Hutchison China Meditech CEO Christian Hogg discusses the importance of capitalizing on opportunities and shares his outlook for biotech. (Source: Bloomberg)
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Hutchison China MediTech Limited Sponsored ADR (NASDAQ: HCM ) will be discussing their earnings results in their H1 Earnings Call to be held on July 27, 2018 ...
Does the share price for Hutchison China MediTech Limited (AIM:HCM) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. IfRead More...